within Pharmacolibrary.Drugs.ATC.C;

model C03EA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03EA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combination of epitizide, a thiazide diuretic, with potassium-sparing agents (such as amiloride or triamterene). Used in the management of hypertension and edema when there is a risk of potassium loss. Marketed primarily as fixed-dose oral formulations. The combination is used today but is not universally available or approved in all countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models or studies with detailed parameters for epitizide and potassium-sparing combination could be found in the literature. Estimated parameters are provided based on similar thiazide/potassium-sparing combinations (e.g., hydrochlorothiazide-amiloride) for adults, oral administration.</p><h4>References</h4><ol><li><p>Fowler, SF, &amp; Murray, KM (1995). Torsemide: a new loop diuretic. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 52(16) 1771–1815. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/52.16.1771&quot;>10.1093/ajhp/52.16.1771</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8528833/&quot;>https://pubmed.ncbi.nlm.nih.gov/8528833</a></p></li><li><p>Manolis, AA, et al., &amp; Manolis, AS (2019). Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives. <i>Vascular health and risk management</i> 15 571–579. DOI:<a href=&quot;https://doi.org/10.2147/VHRM.S210150&quot;>10.2147/VHRM.S210150</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31920323/&quot;>https://pubmed.ncbi.nlm.nih.gov/31920323</a></p></li><li><p>Runci, FM, et al., &amp; Giorgi, G (1989). Kinetics of amiloride in rat following oral and intravenous administration. <i>Bollettino della Societa italiana di biologia sperimentale</i> 65(10) 939–943. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2624711/&quot;>https://pubmed.ncbi.nlm.nih.gov/2624711</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03EA03;
